Grail Stock Rises 34% Ahead of FDA Review for Multi-Cancer Blood Test
Audio narration · Coming soon
Grail's stock surged by 34% as the company prepares for a premarket approval meeting with the FDA regarding its multi-cancer blood test. This review marks a significant step for the potential approval of a landmark cancer detection technology.
Why this matters
PRISM scored this story 65/100 for interest.
Originally published by gnews